BioSpace News Archive

In Q2 2023, Amador Bioscience, a next generation CRO focusing on translational science and early clinical development, announced the addition of Dr. Lorin Roskos to the Board of Directors.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced that it has received a grant of over USD 1.5M from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health.

Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has strengthened its commercial organization with the promotion of Glenn E. Pauly to Chief Commercial Officer and the appointments of Dina Lynch to Vice President of Market Access, and Nate Greene to Vice President of Brand Marketing.

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer.

RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2.

Science 37 Holdings, Inc. announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time.

TELA Bio, Inc., announced that it took part in a segment in Connecting the Dots, a series of branded films presented by MedTech Europe and including a film produced for them by BBC StoryWorks Commercial Productions.